These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 32653448)

  • 1. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.
    Hahn VS; Yanek LR; Vaishnav J; Ying W; Vaidya D; Lee YZJ; Riley SJ; Subramanya V; Brown EE; Hopkins CD; Ononogbu S; Perzel Mandell K; Halushka MK; Steenbergen C; Rosenberg AZ; Tedford RJ; Judge DP; Shah SJ; Russell SD; Kass DA; Sharma K
    JACC Heart Fail; 2020 Sep; 8(9):712-724. PubMed ID: 32653448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
    Hahn VS; Knutsdottir H; Luo X; Bedi K; Margulies KB; Haldar SM; Stolina M; Yin J; Khakoo AY; Vaishnav J; Bader JS; Kass DA; Sharma K
    Circulation; 2021 Jan; 143(2):120-134. PubMed ID: 33118835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between systolic ejection time and outcomes in heart failure by ejection fraction.
    Patel PA; Ambrosy AP; Phelan M; Alenezi F; Chiswell K; Van Dyke MK; Tomfohr J; Honarpour N; Velazquez EJ
    Eur J Heart Fail; 2020 Jul; 22(7):1174-1182. PubMed ID: 31863532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction.
    Yang H; Li R; Ma F; Wei Y; Liu Y; Sun Y; He X; Zeng H; Yan J; Wang DW; Wang H
    ESC Heart Fail; 2022 Dec; 9(6):4280-4290. PubMed ID: 36128643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
    Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
    Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiac amyloidosis: a significant blind spot of the H2FPEF score.
    Duca F; Rettl R; Binder C; Dusik F; Schrutka L; Dalos D; Öztürk B; Capelle CD; Qin H; Dachs TM; Camuz Ligios L; Agis H; Kain R; Hengstenberg C; Badr-Eslam R; Kastner J; Bonderman D
    Panminerva Med; 2023 Dec; 65(4):491-498. PubMed ID: 36789997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
    JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.
    Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial.
    Vaduganathan M; Claggett BL; Chatterjee NA; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Hegde SM; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):653-661. PubMed ID: 29501806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
    Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
    ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.